OUR VISION
To become a global leader in next-generation nanomedicine by redefining how advanced therapeutics are delivered and translated into meaningful treatments for patients.
Our Vision
HERMEZ NANOMEDICINE
Pioneering the Uncharted Frontiers of Nanomedicine
Hermez represents the spirit of exploring beyond the known—challenging established boundaries and advancing new possibilities in nanomedicine.
At Hermez Nanomedicine, we develop next-generation nanotechnology and innovative drug-delivery platforms designed to overcome critical therapeutic barriers, improve delivery efficiency, and expand the potential of advanced medicines.
Our mission is to transform promising science into clinically meaningful therapies by enabling medicines to reach the right target, at the right dose, with greater precision and therapeutic impact.
Through innovation in nanomedicine, we aim to unlock new treatment opportunities for diseases where conventional approaches remain limited.
Explore Beyond.
Deliver Beyond.
Transform Medicine.
Our Vision
Our Team
Hermez Nanomedicine is advancing a precision-engineered, clinically scalable delivery architecture designed to redefine how medicines are translated from molecular discovery to global deployment.
Ivy Hsu, Ph.D., MBA
Founder, Chairman & CEO
Education
- Ph.D., Michigan State University, East Lansing, MI, USA
- Master of Science, Texas A&M University, TX, USA
- M.S. in Management of Technology, National Yang Ming Chiao Tung University
Professional Background
- Founder, Hermez Nanomedicine
- Jointly Appointed Professor, Departments of Bioscience Technology and Chemistry, Chung Yuan Christian University
- Founding Director, Center for Cancer Diagnosis, Therapy R&D and Commercialization, Chung Yuan Christian University
- Appointed by the National Development Fund, Executive Yuan, as corporate director of Deyang Venture Capital Co., Ltd., Shenghua Venture Capital Co., Ltd., and Shengyuan Venture Capital Co., Ltd.
- Manager of International Business Development and Technology Transfer, Laboratory of Biomedical Technology and Device, Industrial Technology Research Institute (ITRI); Principal Investigator for R&D and government policy/industry programs of ITRI; Consultant of ITRI
- Postdoctoral Research Fellow, Academia Sinica
Expertise
- Technology commercialization, business development, startup management, and technology licensing in & out
- Nanomedicine translation, liposome technology, gene therapy, and photodynamic therapy
Jacqueline Liu, MD
Chief Medical Officer
Education
- Bachelor of Medicine and Surgery, University of the Witwatersrand, South Africa
- Internal Medicine Resident and Hematology/Oncology Fellow, Taipei Veterans General Hospital
Professional Background
- Chief Medical Officer, TOT BIOPHARM
- Head of Clinical Development for Taiwan and Korea, BeiGene
- Head of Cancer Translational Center, TTY Biopharm Company Limited
- Attending Physician and Assistant Research Fellow, National Health Research Institutes
Expertise
- Clinical development: Phase 1–3 clinical trial strategy and execution
- Oncology drug development and translational research
- Regulatory consulting and interactions with NMPA, FDA, TFDA, PMDA, and other regulatory agencies
- Drug safety
Sam Hsieh, MD
Director
Education
- M.D., School of Medicine, National Yang Ming Chiao Tung University
Professional Background
- Attending Physician, Thoracic Surgery, China Medical University Hsinchu Hospital
- Director of Thoracic Surgery, Taoyuan Hospital, Ministry of Health and Welfare
- Director, Department of Thoracic Surgery, Shin Kong Wu Ho-Su Memorial Hospital
- Clinical Research Fellow in Thoracic Surgery, University of Pennsylvania, USA
- National Taiwan University Hospital Thoracic Surgery
- Resident and Chief Resident, Armed Forces Taoyuan General Hospital
Expertise
- Clinical application guidance and consultation
Albert Wang
Supervisor
Education
- EMBA, Helsinki School of Economics, Finland
- M.S. in Management of Technology, National Chiao Tung University
Professional Background
- Adjunct Professor, Biomedical EMBA Program, National Yang Ming Chiao Tung University
- Adjunct Professor, Department of Information Management and Finance, National Yang Ming Chiao Tung University
- Division Director, Quanmao Precision Technology
- Section Manager, Taiwan Semiconductor Manufacturing Company (TSMC)
Expertise
- Corporate strategy
- Enterprise information integration
- Corporate negotiation
Sylvia Yin
Corporate Attorney
Education
- Master’s Degree in Advertising and Public Relations Communication, Michigan State University
- Master’s Program in Law for Professionals, Soochow University
Professional Background
- Board Director, Young Women’s Christian Association of Taipei (YWCA Taipei)
- Board Director, Yuanfang Future Medicine Foundation
- Board Director, Penghu Ocean Foundation
- Junior Partner, Li Mo & Associates
- Assistant Manager, Media and Cultural Affairs, Australian Commerce and Industry Office
- Senior Account Executive (Corporate PR & Marketing Strategy), Ogilvy PR
Expertise
- Business strategy development and negotiation
- Fundraising strategy
- Drafting investment agreements, commercial contracts, and non-disclosure agreements
Our Vision
Our Team
Hermez Nanomedicine is advancing a precision-engineered, clinically scalable delivery architecture designed to redefine how medicines are translated from molecular discovery to global deployment.
Ivy Hsu, Ph.D. MBA
Founder, Chairman & Chief Executive Officer
Education
- Ph.D., Michigan State University, East Lansing, MI, USA
- Master of Science, Texas A&M University, TX, USA
- M.S. in Management of Technology, National Yang Ming Chiao Tung University
Professional Background
- Founder, Hermez Nanomedicine Corp.
- Jointly Appointed Professor, Departments of Bioscience Technology and Chemistry, Chung Yuan Christian University
- Founding Director, Center for Cancer Diagnosis, Therapy R&D and Commercialization, Chung Yuan Christian University
- Appointed by the National Development Fund, Executive Yuan, as corporate director of Deyang Venture Capital Co., Ltd., Shenghua Venture Capital Co., Ltd., and Shengyuan Venture Capital Co., Ltd.
- Manager of International Business Development and Technology Transfer, Laboratory of Biomedical Technology and Device, Industrial Technology Research Institute (ITRI); Principal Investigator for R&D and government policy/industry programs of ITRI; Consultant of ITRI
- Postdoctoral Research Fellow, Academia Sinica
Expertise
- Technology commercialization, business development, startup management, and technology licensing in & out
- Nanomedicine translation, liposome technology, gene therapy, and photodynamic therapy
Ivy Hsu, Ph.D., is a scientist, entrepreneur, and biotechnology executive with over 30 years of experience in biomedical research, nanomedicine, translational drug development, technology commercialization, and venture creation. She is Founder, Chairman and CEO of Hermez Nanomedicine, Professor at Chung Yuan Christian University (CYCU), and Founding Director of the Center for Cancer Theranostics and Technology Commercialization. Prior to founding Hermez, Ivy spent approximately a decade at the Industrial Technology Research Institute (ITRI), leading biomedical R&D projects, technology transfer, government-sponsored initiatives, and international collaborations and business development. She contributed to more than 30 biomedical technology licensing-in and licensing-out projects and multiple biotech ventures and spin-offs. Her expertise spans translational nanomedicine, advanced drug delivery, lipid nanoparticles (LNPs), oncology, and gene therapy, bridging academic discovery with CMC & GMP manufacturing, preclinical translation, intellectual property, licensing, and commercialization. She has authored over 40 scientific publications and holds or has contributed to more than 40 patents, with significant technology-transfer achievements. Her honors include the Taiwan Society for Nanomedicine Outstanding Technology Award (2026), National Innovation Awards (2018, 2021, 2025), NSTC Future Tech Award (2022), and Patent Silver Award (2022). Her LNP technology was selected for the Stanford SPARK Global Program in 2024 and 2025. Ivy holds a Ph.D. from Michigan State University, an M.S. from Texas A&M University, and an MBA in Management of Technology from National Yang Ming Chiao Tung University.
Jacqueline Liu, MD
Chief Medical Officer
Education
- Bachelor of Medicine and Surgery, University of the Witwatersrand, South Africa
- Internal Medicine Resident and Hematology/Oncology Fellow, Taipei Veterans General Hospital
Professional Background
- Chief Medical Officer, TOT BIOPHARM
- Head of Clinical Development for Taiwan and Korea, BeiGene
- Head of Cancer Translational Center, TTY Biopharm Company Limited
- Attending Physician and Assistant Research Fellow, National Health Research Institutes
Expertise
- Clinical development: Phase 1–3 clinical trial strategy and execution
- Oncology drug development and translational research
- Regulatory consulting and interactions with NMPA, FDA, TFDA, PMDA, and other regulatory agencies
- Drug safety
Dr. Jacqueline Liu is a physician-scientist with extensive 30 years’ experience in oncology, clinical development, and translational research. She has dedicated her career to advancing innovative cancer therapies and supporting the development of new medicines from early research to clinical application. Her has held key leadership roles in the biopharmaceutical industry, including Chief Medical Officer at TOT BIOPHARM, Head of Clinical Development for Taiwan and Korea at BeiGene, and Head of the Cancer Translational Center at TTY Biopharm. She also served as an Attending Physician and Assistant Research Fellow at the National Health Research Institutes. Her received her Bachelor of Medicine and Surgery from the University of the Witwatersrand, South Africa, and completed her Internal Medicine residency and Hematology/Oncology fellowship at Taipei Veterans General Hospital. Her expertise includes global clinical development, regulatory strategy, drug safety, and Phase 1–3 clinical trial design and execution.
Nick Lee
Operation Advisor
Education
- Bachelor of Science in Pharmacy, China Medical University, Taiwan
- Bachelor of Laws, National Taiwan University, Taiwan
Professional Background
- General Manager, Rxilient Medical Taiwan
- General Manager, Ipsen Pharma Taiwan, Hong Kong & Macau Cluster
- CEO China, SOTIO Biotech
- Attaché to Senior VP, Asia Region
Expertise
- Pharmaceutical general management and business operations
- Start-up establishment, organizational transformation and multi-market business expansion
- Commercialization, new product launches and portfolio strategy
- Business development, licensing and strategic alliances
Nick Lee is a pharmaceutical executive with over 30 years of experience in the pharmaceutical industry across Taiwan, China, Hong Kong, Macau and APAC region. He has held senior leadership positions at Rxilient Medical, Ipsen, SOTIO, Sanofi and Bristol Myers Squibb, with extensive experiences in general management, business development, commercialization, market access, product launches, portfolio strategy and organizational development. His industry expertise covers oncology, rare diseases, neuroscience, specialty care and innovative pharmaceutical products. Nick has successfully built and transformed pharmaceutical organizations, led business expansion and product launches, and developed high-performing teams across the Asia-Pacific region. Nick holds a Bachelor of Science degree in Pharmacy from China Medical University and a Bachelor of Law from National Taiwan University and MBA.
Sam Hsieh, MD
Board Director
Education
- M.D., School of Medicine, National Yang Ming Chiao Tung University
Professional Background
- Attending Physician, Thoracic Surgery, China Medical University Hsinchu Hospital
- Director of Thoracic Surgery, Taoyuan Hospital, Ministry of Health and Welfare
- Director, Department of Thoracic Surgery, Shin Kong Wu Ho-Su Memorial Hospital
- Clinical Research Fellow in Thoracic Surgery, University of Pennsylvania, USA
- National Taiwan University Hospital Thoracic Surgery
- Resident and Chief Resident, Armed Forces Taoyuan General Hospital
Expertise
- Clinical application guidance and consultation
Dr. Sam Hsieh serves as a Board Director of Hermez Nanomedicine, bringing extensive clinical and leadership experience in thoracic surgery and oncology. He is an Attending Physician in Thoracic Surgery at China Medical University Hsinchu Hospital and previously served as Director of Thoracic Surgery at Taoyuan Hospital and Shin Kong Wu Ho-Su Memorial Hospital. His clinical and academic experience includes thoracic surgery at National Taiwan University Hospital and a Clinical Research Fellowship at the University of Pennsylvania, USA. He received his M.D. from National Yang Ming Chiao Tung University. His provides Hermez with valuable clinical perspectives on thoracic oncology, surgical care, and unmet medical needs, supporting the clinical translation, application strategy, and development of innovative therapeutic technologies.
Albert Wang
Board Supervisor
Education
- EMBA, Helsinki School of Economics, Finland
- M.S. in Management of Technology, National Chiao Tung University
Professional Background
- Adjunct Professor, Biomedical EMBA Program, National Yang Ming Chiao Tung University
- Adjunct Professor, Department of Information Management and Finance, National Yang Ming Chiao Tung University
- Division Director, Quanmao Precision Technology
- Section Manager, Taiwan Semiconductor Manufacturing Company (TSMC)
Expertise
- Corporate strategy
- Enterprise information integration
- Corporate negotiation
Mr. Albert Wang serves as Board Supervisor of Hermez Nanomedicine, providing independent oversight of the Company’s corporate governance, financial integrity, and management accountability.
His academic and professional experience includes serving as Adjunct Professor in the Biomedical EMBA Program and in the Department of Information Management and Finance at National Yang Ming Chiao Tung University. He earned his EMBA from the Helsinki School of Economics, Finland, and his M.S. in Management of Technology from National Chiao Tung University.
As Board Supervisor, Mr. Wang oversees the Company’s corporate governance and executive compensation, and is responsible for examining the statements and accounts prepared by the Board of Directors for submission to the shareholders’ meeting — including the business report, the financial statements, and the proposals for distribution of profits or offsetting of losses. His oversight safeguards shareholder interests and reinforces the Company’s commitment to transparency, sound financial management, and accountable governance.
Sylvia Yin
Corporate Attorney
Education
- Master’s Degree in Advertising and Public Relations Communication, Michigan State University
- Master’s Program in Law for Professionals, Soochow University
Professional Background
- Board Director, Young Women’s Christian Association of Taipei (YWCA Taipei)
- Board Director, Yuanfang Future Medicine Foundation
- Board Director, Penghu Ocean Foundation
- Junior Partner, Li Mo & Associates
- Assistant Manager, Media and Cultural Affairs, Australian Commerce and Industry Office
- Senior Account Executive (Corporate PR & Marketing Strategy), Ogilvy PR
Expertise
- Business strategy development and negotiation
- Fundraising strategy
- Drafting investment agreements, commercial contracts, and non-disclosure agreements
An independent corporate attorney advising startups in semiconductor design, telemedicine, biotechnology, and cross-border real estate advisory, with a focus on business strategy, negotiation, fundraising, corporate transactions, and legal compliance. Her practice includes drafting and negotiating angel-round investment agreements, shareholders’ agreements, commercial contracts, non-disclosure agreements, and advising on labor law compliance. She previously served as a Junior Partner at Li Mo & Associates. Earlier in her career, she worked in corporate communications and international affairs, including roles at Ogilvy PR in corporate public relations and marketing strategy and as Assistant Manager for Media and Cultural Affairs at the Australian Commerce and Industry Office. She holds a B.A. in Political Science from National Taiwan University and an M.A. in Advertising and Public Relations Communication from Michigan State University and studied in the Master Program in Law for Professionals at Soochow University. She currently serves as a Board Director of YWCA Taipei, the Yuanfang Future Medicine Foundation, and the Penghu Ocean Foundation.
Our Vision
Our Team
Hermez Nanomedicine is advancing a precision-engineered, clinically scalable delivery architecture designed to redefine how medicines are translated from molecular discovery to global deployment.
Ivy Hsu, Ph.D., MBA
Founder, Chairman & CEO
Ivy Hsu, Ph.D., is Founder, Chairman and CEO of Hermez Nanomedicine, Professor at Chung Yuan Christian University, and Founding Director of its Center for Cancer Diagnosis, Therapy R&D and Commercialization. A scientist and entrepreneur with over 30 years’ experience, she spent about a decade at the Industrial Technology Research Institute (ITRI), leading R&D, technology transfer, government programs and international business development, and contributed to more than 30 licensing projects and biotech spin-offs. Her expertise spans lipid nanoparticles, drug delivery, oncology and gene therapy, bridging lab discovery and commercialization. She has authored over 40 publications and holds or contributed to more than 40 patents. Her honors include the Taiwan Society for Nanomedicine Outstanding Technology Award, three National Innovation Awards and the NSTC Future Tech Award, and her LNP technology was selected for Stanford SPARK. She holds degrees from Michigan State University, Texas A&M University and National Yang Ming Chiao Tung University.
Current Positions
- Founder, Chairman & Chief Executive Officer, Hermez Nanomedicine Corp.
- Jointly Appointed Professor, Departments of Bioscience Technology and Chemistry, Chung Yuan Christian University
- Founding Director, Center for Cancer Diagnosis, Therapy R&D and Commercialization, Chung Yuan Christian University
- Appointed by the National Development Fund, Executive Yuan, as corporate director of Deyang Venture Capital Co., Ltd., Shenghua Venture Capital Co., Ltd., and Shengyuan Venture Capital Co., Ltd.
Experience
- Manager of International Business Development and Technology Transfer, Laboratory of Biomedical Technology and Device, Industrial Technology Research Institute (ITRI); Principal Investigator for R&D and government policy/industry programs of ITRI; Consultant of ITRI
- Postdoctoral Research Fellow, Academia Sinica
Education
- Ph.D., Michigan State University, East Lansing, MI, USA
- Master of Science, Texas A&M University, TX, USA
- M.S. in Management of Technology, National Yang Ming Chiao Tung University
Expertise
- Technology commercialization, business development, startup management, and technology licensing in & out
- Nanomedicine translation, liposome technology, gene therapy, and photodynamic therapy
Jacqueline Liu, MD
Chief Medical Officer
Jacqueline Liu, MD, is a physician-scientist with 30 years of experience in oncology, clinical development and translational research. She has dedicated her career to advancing innovative cancer therapies, guiding new medicines from early research to clinical application. She has held key leadership roles in the biopharmaceutical industry, including Chief Medical Officer at TOT BIOPHARM, Head of Clinical Development for Taiwan and Korea at BeiGene, and Head of the Cancer Translational Center at TTY Biopharm. She also served as an Attending Physician and Assistant Research Fellow at the National Health Research Institutes. Her expertise includes global clinical development, regulatory strategy, drug safety, and Phase 1–3 clinical trial design and execution. She received her Bachelor of Medicine and Surgery from the University of the Witwatersrand, South Africa, and completed her internal medicine residency and hematology/oncology fellowship at Taipei Veterans General Hospital.
Professional Background
- Chief Medical Officer, TOT BIOPHARM
- Head of Clinical Development for Taiwan and Korea, BeiGene
- Head of Cancer Translational Center, TTY Biopharm Company Limited
- Attending Physician and Assistant Research Fellow, National Health Research Institutes
Education
- Bachelor of Medicine and Surgery, University of the Witwatersrand, South Africa
- Internal Medicine Resident and Hematology/Oncology Fellow, Taipei Veterans General Hospital
Expertise
- Clinical development: Phase 1–3 clinical trial strategy and execution
- Oncology drug development and translational research
- Regulatory consulting and interactions with NMPA, FDA, TFDA, PMDA, and other regulatory agencies
- Drug safety
Sam Hsieh, MD
Board Director
Sam Hsieh, MD, serves as a Board Director of Hermez Nanomedicine, bringing extensive clinical and leadership experience in thoracic surgery and oncology. He is currently an Attending Physician in Thoracic Surgery at China Medical University Hsinchu Hospital and previously served as Director of Thoracic Surgery at Taoyuan Hospital, Ministry of Health and Welfare, and at Shin Kong Wu Ho-Su Memorial Hospital. His clinical and academic training includes thoracic surgery at National Taiwan University Hospital, a residency at Armed Forces Taoyuan General Hospital, and a Clinical Research Fellowship at the University of Pennsylvania, USA. He received his M.D. from National Yang Ming Chiao Tung University. Dr. Hsieh provides Hermez with valuable clinical perspectives on thoracic oncology, surgical care and unmet medical needs, supporting the clinical translation, application strategy and development of innovative therapeutic technologies.
Current Positions
- Board Director, Hermez Nanomedicine Corp.
- Attending Physician, Thoracic Surgery, China Medical University Hsinchu Hospital
Professional Background
- Director of Thoracic Surgery, Taoyuan Hospital, Ministry of Health and Welfare
- Director, Department of Thoracic Surgery, Shin Kong Wu Ho-Su Memorial Hospital
- Clinical Research Fellow in Thoracic Surgery, University of Pennsylvania, USA
- National Taiwan University Hospital Thoracic Surgery
- Resident and Chief Resident, Armed Forces Taoyuan General Hospital
Education
- M.D., School of Medicine, National Yang Ming Chiao Tung University
Expertise
- Clinical application guidance and consultation
Albert Wang
Board Supervisor
Albert Wang serves as Board Supervisor of Hermez Nanomedicine, providing independent oversight of the Company’s corporate governance, financial integrity and management accountability. He brings experience spanning industry and academia, having served as Adjunct Professor in the Biomedical EMBA Program and the Department of Information Management and Finance at National Yang Ming Chiao Tung University, Division Director at Quanmao Precision Technology, and Section Manager at TSMC. As Board Supervisor, he oversees corporate governance and executive compensation, and examines the business report, financial statements and profit-distribution or loss-offsetting proposals prepared by the Board for the shareholders’ meeting. His oversight safeguards shareholder interests and reinforces the Company’s commitment to transparency and sound financial management. He holds an EMBA from the Helsinki School of Economics, Finland, and an M.S. in Management of Technology from National Chiao Tung University.
Current Positions
- Board Supervisor, Hermez Nanomedicine Corp.
- Adjunct Professor, Biomedical EMBA Program, National Yang Ming Chiao Tung University
- Adjunct Professor, Department of Information Management and Finance, National Yang Ming Chiao Tung University
Professional Background
- Division Director, Quanmao Precision Technology
- Section Manager, Taiwan Semiconductor Manufacturing Company (TSMC)
Education
- EMBA, Helsinki School of Economics, Finland
- M.S. in Management of Technology, National Chiao Tung University
Expertise
- Corporate strategy
- Enterprise information integration
- Corporate negotiation
Nick Lee
Operations Advisor
Nick Lee is a pharmaceutical executive with over 30 years of experience across Taiwan, China, Hong Kong, Macau and the wider Asia-Pacific region. He has held senior leadership positions at Rxilient Medical, Ipsen, SOTIO, Sanofi and Bristol Myers Squibb, with extensive experience in general management, business development, commercialization, market access, product launches, portfolio strategy and organizational development. His industry expertise covers oncology, rare diseases, neuroscience, specialty care and innovative pharmaceutical products. Nick has successfully built and transformed pharmaceutical organizations, led business expansion and product launches, and developed high-performing teams across the region. He currently serves as Operations Advisor, bringing deep regional insight into start-up establishment, licensing and strategic alliances. He holds a Bachelor of Science in Pharmacy from China Medical University, a Bachelor of Laws from National Taiwan University, and an MBA.
Professional Background
- General Manager, Rxilient Medical Taiwan
- General Manager, Ipsen Pharma Taiwan, Hong Kong & Macau Cluster
- CEO China, SOTIO Biotech
- Attaché to Senior VP, Asia Region
Education
- Bachelor of Science in Pharmacy, China Medical University, Taiwan
- Bachelor of Laws, National Taiwan University, Taiwan
Expertise
- Pharmaceutical general management and business operations
- Start-up establishment, organizational transformation and multi-market business expansion
- Commercialization, new product launches and portfolio strategy
- Business development, licensing and strategic alliances
Sylvia Yin
Corporate Attorney
Sylvia Yin is an independent corporate attorney advising startups in semiconductor design, telemedicine, biotechnology and cross-border real estate, with a focus on business strategy, negotiation, fundraising, corporate transactions and legal compliance. Her practice includes drafting and negotiating angel-round investment agreements, shareholders’ agreements, commercial contracts and non-disclosure agreements, as well as advising on labor law compliance. She previously served as a Junior Partner at Li Mo & Associates. Earlier in her career, she worked in corporate communications and international affairs at Ogilvy PR and the Australian Commerce and Industry Office. She currently serves as a Board Director of YWCA Taipei, the Yuanfang Future Medicine Foundation and the Penghu Ocean Foundation. She holds a B.A. in Political Science from National Taiwan University and an M.A. in Advertising and Public Relations Communication from Michigan State University, and studied in the Master’s Program in Law for Professionals at Soochow University.
Current Positions
- Board Director, Young Women’s Christian Association of Taipei (YWCA Taipei)
- Board Director, Yuanfang Future Medicine Foundation
- Board Director, Penghu Ocean Foundation
Professional Background
- Junior Partner, Li Mo & Associates
- Assistant Manager, Media and Cultural Affairs, Australian Commerce and Industry Office
- Senior Account Executive (Corporate PR & Marketing Strategy), Ogilvy PR
Education
- B.A. in Political Science, National Taiwan University
- Master’s Degree in Advertising and Public Relations Communication, Michigan State University
- Master’s Program in Law for Professionals, Soochow University
Expertise
- Business strategy development and negotiation
- Fundraising strategy
- Drafting investment agreements, commercial contracts, and non-disclosure agreements
Audrey Tseng
Corporate Consultant
Audrey Tseng is Honorary Vice Chairman of PwC Taiwan and serves as an Independent Director of Delta Electronics and ASUSTeK Computer. She also holds vice chairmanships at Taiwan’s digital health and precision medicine industry associations and is an Executive Director of the Taiwan Bio Industry Organization. Over a 35-year career, she was the certifying accountant for the Taiwan Stock Exchange, Delta, ASUS, WPG and TECO, and held senior PwC roles including Vice Chairman, Chief Strategy Officer and Greater China Chief Synergy Officer. For nearly three decades, she has guided dozens of biotech and medical device companies from startup planning and fundraising to IPOs and M&A. PwC-audited biotech firms now represent over half of Taiwan’s listed biotech market value. She has advised the Executive Yuan and the Ministry of Health and Welfare, and is known as Taiwan’s “Godmother of Biotech.” She holds master’s degrees from National Taiwan University–Fudan and National Chengchi University.
Education
- Master’s Degree, College of Management, National Taiwan University / School of Management, Fudan University
- Master’s Degree, Graduate Institute of Accounting, National Chengchi University
Professional Background
- Honorary Vice Chairman, PwC Taiwan
- Independent Director, Delta Electronics, Inc.
- Independent Director, ASUSTeK Computer Inc.
- Vice Chairman, Taiwan Digital Health Industry Development Association
- Vice Chairman, Taiwan Precision Medicine Industry Development Association
- Executive Director, Taiwan Bio Industry Organization (TBIO)
- Member, Bio-Taiwan Committee (BTC), Executive Yuan
- Chief Synergy Officer, PwC Greater China
Expertise
- 35 years as certifying accountant for Taiwan Stock Exchange, Delta Electronics, ASUS, WPG Holdings, TECO and other corporate groups
- Guided dozens of biotech and medical device companies from startup planning to successful IPOs and M&A
